UK biotech Circassia has finally given up on its allergy drug development business, citing difficulties in overcoming a strong placebo effect in the trials required for approval by regulators. After a ...

The UK biotech company is putting its huge failure in allergy treatment behind it with a new deal with AstraZeneca (AZ). But British venture capital leader David Grainger is highly critical of the ...

With the business potentially at an important milestone, we thought we'd take a closer look at Circassia Group Plc's (LON:CIR) future prospects. Circassia Group Plc, a medical device company, focuses ...

A look at the shareholders of Circassia Group Plc (LON:CIR) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a ...

OXFORD, England, January 19 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has initiated phase II clinical trials of its T-cell ...

- Study Provides Proof-of-Concept for Commercial Formulation and Final Stage of Development Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that the company's ...

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the start of a pivotal phase 3 trial of its investigational ToleroMune® cat allergy treatment for cat ...

Shares in UK biotech Circassia have plummeted after its flagship experimental cat allergy drug failed to hit targets in a Phase III trial. Shares in UK biotech Circassia have plummeted after its ...

A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble By Paul Sandle LONDON (Reuters) - Britain's Circassia has secured the U.S. rights from ...

OXFORD, England, September 11, 2012--Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the appointment of Dr Brett Haumann as Chief Medical Officer. Dr Haumann ...

LONDON (Reuters) - Circassia Pharmaceuticals, a British company developing allergy therapies, said on Friday it had agreed to buy Sweden's Aerocrine and privately held Prosonix, two companies focused ...